Cytyc Reaffirms Intention to Complete All Cash Tender Offer for Vision Systems Limited

Notes That New Ventana Litigation Against Vision Systems Does NotImpede Intention To Complete Offer

Remains Confident That Tender Offer Has No Risk Of AntitrustIssues

Cytyc Corporation (Nasdaq: CYTC) today issued the followingstatement regarding its A$2.35 all cash tender offer for VisionSystems Limited (ASX: VSL):

"We have carefully examined the patent litigation filed onSeptember 18, 2006 by Ventana Medical Systems, Inc. (Nasdaq: VMSI)against a subsidiary of Vision Systems. This litigation involves U.S.Patent No. 6,594,537. We are completely satisfied that this newlitigation will not stand in the way of our intention to complete thistender offer -- and to deliver the superior value of our offer toVision Systems shareholders -- as quickly as possible. Accordingly, wedo not regard the filing of this litigation as a material adversechange in relation to the offer.

"We are aware that the Australian Competition & ConsumerCommission has commenced an informal review of Ventana's proposal toacquire Vision Systems as well as our tender offer. We are pleased tocooperate with the Commission's informal review. Vision Systemsshareholders should know that Cytyc remains confident that our tenderoffer has no risk of antitrust issues because, unlike Ventana, Cytycis not a competitor of Vision Systems."

On September 15, 2006 Cytyc lodged its Bidder's Statement for itsall cash tender offer to acquire Vision Systems for A$2.35 peroutstanding share, or a total consideration of A$497 million (US$374million). Cytyc has also requested approval from the Vision SystemsBoard of Directors for early dispatch of the Bidder's Statement toVision Systems shareholders to allow them to take advantage of theoffer as soon as possible. Cytyc is seeking a favorable recommendationfrom the Vision Systems Board because Cytyc's offer is all cash, is ata higher price than the Ventana proposal, has fewer conditions thanthe Ventana proposal and therefore has greater certainty of payment.

ABOUT CYTYC CORPORATION

Cytyc Corporation is a leading provider of best-in-class medicaltechnology that enables physicians and laboratories to improvepatient's lives throughout the world. Cytyc provides diagnostic andminimally invasive surgical products targeting cancer and women'shealth. The ThinPrep(R) System is the most widely used method forcervical cancer screening in the United States. The ThinPrep Systemconsists of the ThinPrep(R) 2000 Processor, ThinPrep(R) 3000Processor, ThinPrep(R) Imaging System, and related reagents, filters,and other supplies. The ThinPrep System also provides the platformfrom which the Company launched its expansion into breast cancer riskassessment with the FirstCyte(R) Breast Test. The MammoSite(R)Radiation Therapy System is a single-use device for the treatment ofbreast cancer that positions radiation sources directly into thepost-lumpectomy site to optimize radiation treatment delivery whileminimizing damage to healthy tissue. The NovaSure(R) ImpedanceControlled Endometrial Ablation System, or the NovaSure(R) System, isan innovative endometrial ablation device to treat menorrhagia, orexcessive menstrual bleeding.

Cytyc is traded on The Nasdaq Stock Market under the symbol CYTC.Cytyc, ThinPrep, NovaSure, MammoSite, and GliaSite are registeredtrademarks of Cytyc Corporation.

ABOUT VISION SYSTEMS LIMITED

Vision Systems operates two core business units: VisionBio-Systems manufactures and markets automated instruments andreagents for biopsy-based detection of cancer and infectious diseasesin pathology laboratories worldwide. Products include the Bond(TM)-maXadvanced staining system, the Peloris(TM) tissue processor, andNovocastra(TM) antibodies and biochemical reagents. Income isgenerated from capital equipment sales, visualization reagents to theBond system and Novocastra branded antibodies used inimmunohistochemistry for the identification of cancer and infectiousdiseases.

The second business unit is Invetech, a worldwide provider ofresearch and development services for both internal and externalclients, primarily in the international healthcare sector.

FORWARD LOOKING STATEMENTS

Forward-looking statements in this press release are made pursuantto the provisions of Section 21E of the Securities Exchange Act of1934. Investors are cautioned that statements in this press releasewhich are not strictly historical statements, including, withoutlimitation, statements relating to Cytyc's future financial condition,operating results and economic performance, and management'sexpectations regarding key customer relationships, future growthopportunities, product acceptance and business strategy, constituteforward-looking statements. These statements are based on currentexpectations, forecasts and assumptions that are subject to risks anduncertainties, which could cause actual outcomes and results to differmaterially from those statements. Risks and uncertainties include,among others, dependence on key personnel and customers as well asreliance on proprietary technology, uncertainty of product developmentefforts and product acceptance, management of growth, productdiversification, and organizational change, entry into new marketsegments domestically and new markets internationally, risksassociated with litigation, the effective integration of acquiredbusinesses and technologies, competition and competitive pricingpressures, risks associated with the FDA regulatory approval processesand healthcare reimbursement policies in the United States and abroad,introduction of technologies that are disruptive to Cytyc's businessand operations, the impact of new accounting requirements andgovernmental rules and regulations, as well as other risks detailed inCytyc's filings with the Securities and Exchange Commission, includingthose under the heading "Risk Factors" in its 2005 Annual Report onForm 10-K and its most recent Quarterly Report on Form 10-Q filed withthe Commission. Cytyc cautions readers not to place undue reliance onany such forward-looking statements, which speak only as of the datethey were made. Cytyc disclaims any obligation to publicly update orrevise any such statements to reflect any change in its expectationsor events, conditions, or circumstances on which any such statementsmay be based, or that may affect the likelihood that actual resultswill differ from those set forth in the forward-looking statements.